Learn what aficamten is, how this next‑generation cardiac myosin inhibitor works in hypertrophic cardiomyopathy (HCM), and why its targeted, tunable mechanism is reshaping treatment options for obstructive HCM.
Discover how artificial intelligence is reshaping pharmacovigilance, from automated case intake and NLP-driven triage to proactive signal detection using real-world data. Learn key AI use cases, benefits, and considerations for compliant, ethical, and future-proof drug safety.
Discover how next‑generation mitochondrial uncouplers boost resting energy expenditure, burn liver and visceral fat, and improve insulin sensitivity by turning excess calories into heat instead of stored fat. Learn why this emerging obesity and NAFLD treatment could complement today’s appetite‑suppressing drugs.
Learn what tirzepatide is, how its dual GIP and GLP‑1 agonist mechanism works, and why it’s outperforming traditional GLP‑1 drugs for type 2 diabetes control and weight loss in SURPASS clinical trials.
Learn what AI-driven pharmacovigilance is and how machine learning, NLP, and intelligent automation are transforming ICSR processing, case triage, and signal detection to improve global drug safety and risk management.
Discover how NEO-201, an investigational monoclonal antibody, targets tumor-associated neoepitopes and abnormal O-glycans to enhance antibody-dependent cellular cytotoxicity (ADCC), reshape the tumor microenvironment, and potentially synergize with checkpoint inhibitors in solid tumor treatment.
Discover how AI-driven pharmacovigilance is reshaping drug safety by automating case intake, enhancing safety signal detection, and analyzing real-world data at scale—improving outcomes for patients, regulators, and the pharmaceutical industry.
Discover how oral GLP‑1 small molecule drugs could transform obesity and type 2 diabetes treatment. Learn how they work, why they may be cheaper and easier than injectables, and their potential to become “statins” for metabolic disease.
Discover how trastuzumab emtansine (T-DM1), a next-generation HER2-targeted antibody–drug conjugate, delivers precision cytotoxic therapy in HER2-positive breast cancer, improves progression-free and overall survival, and reduces off-target toxicity compared with conventional chemotherapy.
Learn what lepuledstat (SAR442168, PRN2246) is, how this brain-penetrant DHODH inhibitor works in multiple sclerosis, and why its precision immunometabolism and CNS-focused action are generating excitement for safer, smarter MS treatment.